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Introduction
Pancreatic carcinoma is a lethal disease, and the incidence 
rates are almost equal to the mortality rates. A major fac-
tor that contributes to the high mortality rate is the propen-
sity of pancreatic cancer cells to invade local tissues and 
disseminate widely throughout the body. The disruption 
of cell–cell adhesion is one of the important factors that 
results in the invasion and metastasis of carcinoma cells. 
Therefore, it would be indispensable to clarify the molecu-
lar mechanisms underlying cell adhesion to better under-
stand the invasion and metastasis of cancer cells.
The epithelial-mesenchymal transition (EMT) is a phe-
nomenon where the epithelial features of cells change to 
mesenchymal features, which can induce the loss of their 
cell polarity; this is associated with invasion and metasta-
sis [1, 2]. E-cadherin, one of the factors associated with the 
EMT, is a member of the transmembrane glycoprotein fam-
ily that is responsible for epithelial cell–cell adhesion, and 
the molecule is expressed by epithelial cells [3]. A reduc-
tion or loss of E-cadherin expression in cancer cells results 
in the destruction of the junctional structure, which can 
affect intercellular adhesion, which promotes tumor migra-
tion and metastasis [4, 5]. The loss of E-cadherin expres-
sion is related to the survival and prognosis of a number of 
cancers, such as extrahepatic bile duct carcinoma, pulmo-
nary adenocarcinoma and pancreatic carcinoma [6].
Nectins are Ca+-independent [2] immunoglobulin-like 
cell adhesion molecules that regulate the formation of 
adherens junctions and tight junctions by epithelial cells 
[9]. They also participate in regulating cellular activi-
ties such as cell polarization and migration [10, 11]. The 
cytoplasmic region of nectins binds afadin, which directly 
connects to the actin cytoskeleton. The nectin–afadin com-
plex is recruited to the E-cadherin-based cell–cell adherens 
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junctions [10, 12]. Four subtypes of nectins are known: 
nectin-1, nectin-2, nectin-3 and nectin-4. Nectins-1, -2 and 
-3 are ubiquitously expressed in a variety of cells, whereas 
nectin-4 is mainly restricted to the placenta in humans [11, 
13]. Recently, the expression patterns and characteristics 
of nectins in various tumors have been reported. For exam-
ple, uterine cervical squamous cell carcinomas expressed 
nectin-1, but the advancing edge of the tumor nests of this 
tumor type had absent or reduced nectin-1 expression com-
pared with the center of the tumor nests [14]. High nectin-2 
expression in gallbladder adenocarcinoma and squamous 
cell aden squamous carcinoma has been shown to be related 
to a poor prognosis [15]. In non-small-cell lung cancer, a 
high level of nectin-4 expression is associated with a poor 
prognosis [16], and the serum level of nectin-4 was signifi-
cantly higher in non-small-cell lung cancer patients than 
healthy tissue donors [16]. Serum nectin-4 has been identi-
fied as a marker of disease progression and therapeutic effi-
ciency, and has been correlated with the number of metas-
tases in breast carcinoma [17]. Similarly, the suppression of 
nectin-1 reduced the levels of cytokeratins-18, beta-catenin, 
claudine-3 and E-cadherin expression in breast cancer cell 
lines [18]. The membranous nectin-3 expression has been 
reported to be related to a poor prognosis in lung adeno-
carcinoma patients [19]. Nuclear factor κB activity is asso-
ciated with the expression of its downstream target genes, 
which leads to tumor progression, and was associated with 
the prognosis in an experimental model of pancreatic can-
cer [20]. However, to the best of our knowledge, there have 
been no evaluations of the importance of the expression 
of different nectin subtypes in pancreatic adenocarcinoma 
with regard to the clinicopathological features of patients. 
However, the expression of E-cadherin and nectins is con-
sidered to be related to the metastasis, invasion and progno-
sis of pancreatic cancer.
In the present study, we performed immunohistochemi-
cal staining for E-cadherin and the nectin subtypes in 49 
pancreatic adenocarcinomas to elucidate whether the 
expression of E-cadherin and nectins was correlated with 
the clinicopathological features and clinical outcomes 
of the patients. In addition, we evaluated the correlation 
between the E-cadherin and nectin expression in pancreatic 
adenocarcinomas.
Materials and methods
Cases and sample preparation
A total of 49 IDC patients were examined in the present 
study. We only evaluated the cases of invasive adenocar-
cinoma, but eliminated adenocarcinomas derived from 
intraductal papillary mucinous neoplasms or special 
histological tumor types, such as aden squamous carci-
noma or anaplastic carcinoma. The patients in our study 
had undergone surgical resection from 2000 to 2005 at 
Tokai University Hospital; all had undergone a routine his-
tological diagnosis. The histological materials were fixed 
in formalin and embedded in paraffin; the sections were 
cut into 4 μm-thick sections and subjected to hematoxy-
lin–eosin (HE) staining.
Immunohistochemistry
Immunohistochemical staining for nectin-1, -2, -3, -4 and 
E-cadherin was performed. The formalin-fixed and par-
affin-embedded materials were cut into 4 μm-thick sec-
tions, which were deparaffinized in xylene and rehydrated 
through a graded ethanol series of decreasing concentra-
tions to distilled water. The immunohistochemical stain-
ing for nectin-3 (polyclonal; dilution, 1:100; Santa Cruz 
Biotechnology, CA, USA) and E-cadherin (clone 36 B5; 
dilution, 1:20; Leica Microsystems, Newcastle upon Tyne, 
United Kingdom) was performed using the Dako auto-
stainer (Dako, Glostrup, Denmark) with antigen retrieval 
by autoclaving the samples for 15 min in a sodium citrate 
buffer at pH 6.0. The antibodies were detected using EnVi-
sion Plus (Dako) with 3,3′-diaminobenzidine as the chro-
mogen. The immunohistochemical staining for nectin-1 
(anti-PVRL1; polyclonal; dilution, 1:100; Sigma, MO, 
USA), nectin-2 (anti-PVRL2; polyclonal; dilution, 1:100; 
Sigma) and nectin-4 (anti-PVRL4; polyclonal; dilution, 
1:100; Sigma) was completed using the BondMax (Leica) 
reagents according to the manufacturer’s manual. Antigen 
retrieval was performed by treatment with ER2 (Leica) for 
30 min for nectin-1 and nectin-2, and with ER1 (Leica) for 
30 min for nectin-4. Appropriate positive and negative tis-
sue control samples were used.
Evaluation of the immunohistochemical staining
The percentage of tumor cells that expressed nectins or 
E-cadherin in the cytoplasm or the membrane in the total 
number of tumor cells was scored as follows: less than 
5 % positive cells, score 0 (negative); 5–29 %, score 1; 
30–59 %, score 2 and over 60 %, score 3. The immunohis-
tochemical results were evaluated by H.I. and K.H.
Statistical analysis
All statistical analyses were performed using the SPSS 
version 19 software program (IBM Japan, Tokyo, Japan). 
For the statistical analysis, the Mann–Whitney U test 
and Kruskal–Wallis test were used to evaluate the differ-
ences between the immunohistochemical scores of nec-
tins or E-cadherin and the clinicopathological findings. 
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Spearman’s rank correlation coefficient was used to cor-
relate the immunohistochemistry scores between the nec-
tins and E-cadherin. Life-table probabilities for the overall 
survival were calculated using the Kaplan–Meier method, 
and the differences in survival between the subgroups were 
compared with the log-rank test. To define independent risk 
factors for the prognosis, a multivariate analysis was per-
formed using a Cox proportional hazards model. A value of 
p < 0.05 was considered to be significant.
Results
Clinical features
The mean age of the 49 patients with pancreatic adeno-
carcinoma was 67 years old (range 50–87). There were 24 
males (49 %) and 25 females (51 %). The mean tumor size 
was 3.5 cm (range 1.5–6.0) in diameter. Eleven cases were 
dominated by well-differentiated adenocarcinoma (G1) 
(22 %), 36 were dominated by moderately differentiated 
adenocarcinoma (G2) (74 %) and two were dominated by 
poorly differentiated adenocarcinoma (G3) (4 %). There 
were 32 cases with lymph node metastasis (65 %) and 17 
without lymph node metastasis (35 %). The mean follow-
up period was 816 days (range 73–3,515). Forty-two out 
of the 49 patients died of the disease, whereas seven were 
still alive at the most recent follow-up. The clinical features 
have been summarized in Table 1.
Nectin immunohistochemistry
Nectin-1 and nectin-3 showed both membranous and cyto-
plasmic expression in the intercalated ducts, intralobular 
ducts and interlobular ducts of the normal pancreas. Nec-
tin-2 showed weak expression in the apical membrane in 
the intercalated ducts, intralobular ducts and interlobular 
ducts of the normal pancreas. There was no nectin-4 stain-
ing in the normal pancreatic ducts, including the interca-
lated ducts. The islet cells were negative for nectin-1, 
whereas nectin-2 and -3 showed membranous and cyto-
plasmic expression in the islet cells; however, the nectin-2 
expression was weak. There was cytoplasmic expression of 
nectin-4 in the islet cells. In the adenocarcinoma cells, nec-
tin-1 and -3 demonstrated both membranous and cytoplas-
mic expression. Nectin-2 and nectin-4 were also expressed 
in the membranes and cytoplasm of the adenocarcinoma 
cells, although the degree of expression was usually weak. 
Representative images showing the expression of nectin-1, 
-2, -3 and -4 in the normal pancreatic parenchyma and in 
pancreatic adenocarcinoma are presented in Fig. 1. The 
immunohistochemical scores for nectins and E-cadherin 
have been summarized in Table 2.
Most of the pancreatic adenocarcinoma cases demon-
strated diffuse nectin-1 (median score: 3.0, mean score: 
2.88) and nectin-3 (median score 3.0, mean score: 2.86) 
expression. There were no cases with a score 0 for nectin-1 
or nectin-3. In contrast, most of the pancreatic adenocar-
cinoma cases showed negative or focal staining for nec-
tin-2 (median score: 1.0, mean score: 0.76) and nectin-4 
(median score: 0, mean score: 0.67). A score of 3 for nec-
tin-4 was observed in two cases (4 %), but there were no 
case with a score of 3 for nectin-2. There were no signifi-
cant differences between the immunohistochemical scores 
of each nectin and the clinicopathological features, includ-
ing lymph node metastasis and gender (Table 1). However, 
the tumors that were over 4 cm in diameter showed higher 
scores for nectin-4 than those that were less than 4 cm in 
diameter (p = 0.035) (Table 1). The nectin-2 expression 
correlated with the tumor grade (p = 0.04) (Table 1).
E-cadherin immunohistochemistry
E-cadherin showed both membranous and cytoplasmic 
expression in the intercalated ducts, intralobular ducts and 
interlobular ducts of the normal pancreas and adenocarci-
noma cells (Fig. 1e, i). E-cadherin was diffusely expressed 
in pancreatic adenocarcinoma (median score: 3.0, mean 
score: 2.78) (Table 2). There were no cases of pancreatic 
adenocarcinoma with a score of 0 for E-cadherin. There 
were no significant differences between the immunohisto-
chemical scores for E-cadherin with regard to the clinico-
pathological features, including lymph node metastasis, the 
size of the tumor, patient gender or histological grade of the 
tumor (Table 1).
Correlation of the immunohistochemical findings 
among nectins and E-cadherin
The immunohistochemical scores for nectin-1 and E-cad-
herin showed a good correlation (r = 0.523, p < 0.01), 
whereas there was no significant correlation in the other 
combinations among the nectins and E-cadherin (Table 3).
The relationship between nectins/E-cadherin expression 
and patient survival
There was no significant difference in the overall survival 
associated with the immunohistochemical scores for nec-
tin-1, nectin-2, nectin-4 or E-cadherin. The patients with 
a score of 3 for nectin-3 showed a better prognosis than 
the cases with scores of 0–2 (p = 0.018) (Fig. 2). We per-
formed a multivariate analysis that included the histologi-
cal grade, lymph node metastasis and tumor size to assess 
the importance of the score of nectin-3. In the multivari-
ate analysis, the score of nectin-3 (p = 0.015; hazard ratio 
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Fig. 1  Representative immu-
nohistochemical staining for 
nectin-1, nectin-2, nectin-3, 
nectin-4 and E-cadherin expres-
sion in the normal pancreatic 
parenchyma (a nectin-1, b 
nectin-2, c nectin-3, d nectin-4, 
e E-cadherin) and in adenocar-
cinoma (f nectin-1, g nec-
tin-2, h nectin-3, i nectin-4, j 
E-cadherin)
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0.360; 95 % confidence interval 0.158–0.832) and tumor 
size (p = 0.014; hazard ratio 0.429; 95 % confidence inter-
val 0.219–0.841) emerged as independent prognostic fac-
tors (Table 4).
Discussion
The EMT plays a key role in the metastasis and invasion 
of various carcinomas. The disruption of the cell–cell adhe-
sion of tumor epithelial cells, resulting in the EMT, causes 
tumor progression and is related to a poor prognosis of can-
cer patients. The EMT leads to the disruption of the adhe-
rens junctions that are composed of E-cadherin. In gen-
eral, E-cadherin expression is strong in well-differentiated 
carcinomas, which often maintain their cell–cell adhesion 
and are less invasive; however, E-cadherin expression is 
reduced in undifferentiated cancers, which have lost their 
cell–cell adhesion and have strong invasive and metastatic 
tendencies [21]. E-cadherin expression was found to be 
absent or at low levels in the metastases of various tumors, 
including pancreatic cancer [8, 22]. Among pancreatic can-
cers, Guo et al. [22] reported that E-cadherin expression 
was significantly lower in pancreatic adenocarcinomas with 
lymph node metastasis compared with the adenocarcino-
mas without lymph node metastasis. Furthermore, several 
groups have reported that pancreatic cancers with the loss 
of E-cadherin had a poorer prognosis; therefore, E-cadherin 
expression has emerged as an independent prognostic fac-
tor [8, 26]. However, our data did not show any correlation 
of the E-cadherin expression with clinicopathological fea-
tures such as lymph node metastasis, the tumor histological 
grade or prognosis. The reason why no significant differ-
ence was obtained was likely due to the small number of 
cases. Significant differences may appear if a larger num-
ber of cases were analyzed.
Nectins may be considered EMT-related molecules 
because they are transferred to E-cadherin via afadin and 
the actin cytoskeleton [10, 12]. There have been only a few 
studies about nectins related to the EMT and E-cadherin. 
Vetter et al. [18] reported that the suppression of nectin-1 
reduced the E-cadherin expression in a breast cancer cell 
line which indicated that nectin-1 correlated with E-cad-
herin expression and the EMT. Our present results revealed 
that nectin-1 showed a good correlation with E-cadherin 
expression, whereas nectins-2, -3 and -4 showed a poor 
correlation with E-cadherin. These results indicated that 
nectin-1 is associated with the EMT via its correlation with 
E-cadherin. However, Matsushima et al. [27] reported that 
the expression of nectin-1α, one of the splice variants of 
Table 2  Score of nectins and 
E-cadherin
SD standard deviation
Score 0 (%) Score 1 (%) Score 2 (%) Score 3 (%) Mean score (SD) Median
Nectin-1 0 1 (2) 4 (8) 44 (90) 2.88 (0.389) 3.0
Nectin-2 15 (31) 31 (63) 3 (6) 0 0.76 (0.56) 1.0
Nectin-3 0 0 7 (14) 42 (86) 2.86 (0.354) 3.0
Nectin-4 25 (51) 17 (35) 5 (10) 2 (4) 0.67 (0.826) 0
E-cadherin 0 1 (2) 9 (18) 39 (80) 2.78 (0.468) 3.0
Table 3  Correlation of immunohistochemical score among nectins 
and E-cadherin
* p < 0.01
Nectin-1 Nectin-2 Nectin-3 Nectin-4 E-cadherin
Nectin-1 1
Nectin-2 0.224 1
Nectin-3 0.071 0.131 1
Nectin-4 −0.02 −0.217 −0.095 1
E-cadherin 0.523* 0.242 0.247 0.051 1
Fig. 2  The overall survival curves according to the nectin-3 expres-
sion
Table 4  Multivariate analysis
CI confidence interval
Variables Hazard ratio 95 % CI p value
Grade (G1/G2, G3) 1.126 0.513–2.469 0.768
Lymph node metastasis 1.127 0.576–2.205 0.726
Tumor size (<4.0 cm/≧4.0 cm) 0.429 0.219–0.841 0.014
Score for nectin-3 (3/2–0) 0.360 0.158–0.832 0.015
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nectin-1, was decreased in well-differentiated squamous 
cell carcinoma and basal cell carcinoma of the skin com-
pared with that in the normal epidermis and Bowen’s dis-
ease, in spite of the preserved E-cadherin expression. In 
addition, Yu et al. [28] reported that the nectin-1 expres-
sion was inversely correlated with E-cadherin expression in 
head and neck squamous carcinoma cell lines. Therefore, 
the role of nectin-1 in tumors is still controversial, and will 
require further studies.
The expression of nectin-2 and nectin-4 has been 
reported to be associated with a poor prognosis in gall-
bladder carcinoma [15] and non-small-cell lung carcinoma 
[16], respectively. Although our present results showed no 
correlation between the expression of nectin-2 and nec-
tin-4 and the patient survival, a higher score for nectin-2 
was related to a poorer histological grade, and a higher 
score for nectin-4 was related to a larger tumor size. These 
results indicated that nectin-2 and nectin-4 may be asso-
ciated with the extent of tumor malignancy in cases of 
pancreatic carcinoma. Furthermore, these findings suggest 
that the downregulation of nectin-4 is associated with the 
loss of cell-to-cell adhesion in pancreatic carcinoma. Fur-
ther studies will be needed to elucidate the mechanism(s) 
by which pancreatic carcinomas downregulate nectin-4 
expression, which can lead to the invasion and spread of 
such carcinomas.
Our present study showed that diffuse nectin-3 expres-
sion was associated with a good prognosis in pancreatic 
adenocarcinoma. However, Maniwa et al. [19] reported that 
membranous nectin-3 expression was an independent prog-
nostic factor for lung adenocarcinoma Furthermore; they 
revealed that membranous nectin-3 expression correlated 
with a higher incidence of pleural invasion, pT factors, dis-
tant metastasis and vascular invasion. Our results demon-
strated that a lack of nectin-3 expression and the tumor size 
were independent prognostic factors. The role of nectins in 
the extent of tumor malignancy, such as its invasion, metas-
tasis and prognosis, may be different depending on the his-
tological types and tumor origins.
In conclusion, the present study is the first to compare 
the expression of nectin subtypes and E-cadherin, and to 
correlate these with the clinicopathological features of pan-
creatic adenocarcinoma. Our results revealed that diffuse 
nectin-3 expression was associated with a good prognosis, 
a higher score for nectin-2 was related to a poorer histo-
logical grade and a higher score for nectin-4 was related to 
a larger tumor size. The malignant characteristics of pan-
creatic cancer cannot be explained by a single factor, and 
some factors are likely to participate in complicated ways 
that involve multiple pathways. In addition, it is thought 
that the expression of nectin-2 and nectin-4 in pancreatic 
cancer was not associated with the outcome; however, a 
significant difference was found in the pathological factor. 
Therefore, the roles of nectins in the invasion and metasta-
sis of carcinoma cells have not yet been clarified.
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